Coagulation Factor Ix Recombinant Human

CHEMBL2109205 Phase 4 Approuvé Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A laboratory-produced version of human clotting factor IX used to treat and prevent bleeding in patients with hemophilia B. It replaces or supplements the missing clotting protein to allow normal blood coagulation.

Aires thérapeutiques

Hematology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A laboratory-produced version of human clotting factor IX used to treat and prevent bleeding in patients with hemophilia B. It replaces or supplements the missing clotting protein to allow normal blood coagulation.

Yes, Coagulation Factor Ix Recombinant Human is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2109205. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Coagulation Factor Ix Recombinant Human sur PillFYI

Données Clés

Synonymes: 2

Liens externes

ChEMBL CHEMBL2109205

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.